论文部分内容阅读
目的探讨左氧氟沙星联合氨溴索治疗肺结核患者肺部感染的临床效果。方法选取2011年4月-2013年1月肺结核合并肺部感染患者136例,随机分为两组,其中对照组65例、观察组71例;两组患者均给予基础营养治疗和常规抗结核治疗,对照组患者同时给予左氧氟沙星静脉滴注,观察组患者给予左氧氟沙星静脉滴注的同时再给予氨溴索静脉滴注,对两组患者的治疗效果进行评价,记录两组患者痰液病原菌转阴时间和病灶吸收情况;采用SPSS13.0软件进行统计分析。结果肺结核合并肺部感染患者治疗显效率和总有效率观察组分别为61.97%和92.96%,对照组分别为47.69%和67.69%;观察组患者痰液病原菌转阴时间为(7.95±2.73)d,对照组为(11.47±3.20)d,观察组明显短于对照组;观察组病灶显著吸收和总吸收率分别为50.70%和84.51%,对照组分别为27.69%和61.54%,观察组患者明显高于对照组,上述比较两组差异有统计学意义(P<0.05);两组患者均无严重不良反应发生。结论对肺结核合并肺部感染患者实施左氧氟沙星沙星联合氨溴索治疗安全而有效,而且用药简单,可以在临床工作中作为常规治疗方式进行推广。
Objective To investigate the clinical effect of levofloxacin combined with ambroxol on pulmonary infection in patients with pulmonary tuberculosis. Methods From April 2011 to January 2013, 136 patients with pulmonary tuberculosis complicated with pulmonary infection were randomly divided into two groups, 65 cases in the control group and 71 cases in the observation group. Both groups were given basic nutrition and routine anti-TB treatment , Patients in the control group were also given intravenous infusion of levofloxacin, intravenous drip of levofloxacin in the observation group was given intravenous infusion of ambroxol to evaluate the therapeutic effect of the two groups of patients, the sputum pathogens in both groups were recorded in the negative conversion time And the absorption of lesions; using SPSS13.0 software for statistical analysis. Results The effective rate and total effective rate of treatment group were 61.97% and 92.96% in the observation group and 47.69% and 67.69% in the control group respectively. The time of sputum pathogenic bacteria in the observation group was (7.95 ± 2.73) d , And the control group was (11.47 ± 3.20) d. The observation group was significantly shorter than the control group. The significant absorption and total absorption rate of the observation group were 50.70% and 84.51% respectively, while the control group was 27.69% and 61.54% respectively. Higher than the control group, the above two groups showed significant difference (P <0.05); no serious adverse reactions occurred in both groups. Conclusions The levofloxacin and cefotaxime combined with ambroxol are safe and effective for patients with pulmonary tuberculosis complicated with pulmonary infection. Moreover, the medication is simple and can be promoted as a routine treatment in clinical practice.